Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SKB518 alone or in combination for advanced gynecologic malignancies
CTR20260595Phase 2Active
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SKB518 in gynecological cancer, sponsored by Sichuan Kelun-Biotech Biopharmaceutical. Started Apr 2026; status: active.
02
Drugs
SKB518
03
Conditions
gynecological cancer
Beyond the preview
Go deeper on CTR20260595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260595.